Risk factors in chronic lymphocytic leukemia, validation of flow cytometric detection using RT-PCR and immunohistochemistry
Authors:
M. Špaček 1; S. Peková 2; L. Bezdíčková 1; T. Kozák 1
Authors‘ workplace:
Oddělení klinické hematologie, 3. lékařská fakulta Univerzity Karlovy v Praze a Fakultní nemocnice Královské Vinohrady, Praha, 2Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha
1
Published in:
Transfuze Hematol. dnes,15, 2009, No. 2, p. 91-96.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Individual prognosis in patients with chronic lymphocytic leukemia (CLL) may be specified by biological risk factors, detection of which must however be sufficiently standardized prior to their introduction into clinical practice. In the presented study of 73 patients we have assessed immunoglobulin variable heavy-chain gene (IgVH) status, presence of mutation in p53 gene and with the use of flow cytometry (FCM) expression of CD38 and ZAP-70 tyrosine kinase. Unmutated IgVH status was present in 58 % patients, p53 mutation in 19 %, positive expression of CD38 in 26 % and positive expression of ZAP-70 using FCM in 62 %. Patients with unmutated IgVH, positive expression of ZAP-70 assessed by FCM and p53 mutation had significantly shorter time from diagnosis to initiation of therapy. Overall concordance between ZAP-70 expression and IgVH mutational status was 85 %. Validation of the FCM ZAP-70 detection was performed by comparison to the immunohistochemical analysis on histological sections and quantitative real-time PCR on the mRNA level; overall concordance was 86 %. Expression of ZAP-70 showed to be stable over time; with median time of 12 months from the acquisition of the first sample to the last, qualitative change of ZAP-70 expression was noted in only one patient, who became positive upon disease progression.
Key words:
chronic lymphocytic leukemia, ZAP-70, IgVH mutation status, CD38, p53, prognosis
Sources
1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–204.
3. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62: 567–575.
4. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern – the best simple prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–648.
5. Sarfati M, Chevret S, Chastang C, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259–4264.
6. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93: 1732–1737.
7. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–1847.
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848.
10. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B cell chronic lymphocytic leukemia. Blood 2001; 98: 181–186.
11. Hamblin TJ, Orchard JA, Ibbotson RE, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023–1029.
12. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–47.
13. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101: 4944–4951.
14. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775.
15. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukemia. Lancet 2004; 363: 105–111.
16. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavychain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Eng J Med 2004; 351: 893–901.
17. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997.
18. Letestu R, Rawstron A, Ghia P, et al. Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. Cytometry B Clin Cytom 2006; 70: 309–314.
19. Le Garff-Tavernier M, Ticchioni M, Brissard M, et al. National standardization of ZAP-70 determination by flow cytometry: the French experience. Clin Cytom 2007; 72: 103–108.
20. Peková S, Marková J, Pajer P, Dvořák M, Cetkovský P, Schwarz J. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. Mol Diagn 2005; 9: 23–34.
21. Smardova J, Ksicova K, Binkova H, et al. Analysis of tumor suppressor p53 status in head and neck squamous cell carcinoma. Oncol Rep 2004; 11: 923–929.
22. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008; 22: 211–219.
23. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.
24. Bosch F, Muntanola A, Giné E, et al. Clinical Implications of ZAP-70 Expression in Chronic Lymphocytic Leukemia. Cytometry B Clin Cytom 2006; 70: 214–217.
25. Bakke AC, Purtzer Z, Leis J, Huang J. A Robust Ratio Metric Method for Analysis of Zap-70 Expression in Chronic Lymphocytic Leukemia (CLL). Cytometry B Clin Cytom 2006; 70B: 227–234.
26. Chen YH, Peterson LC, Dittmann D, et al. Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. Am J Clin Pathol 2007; 127: 182–191.
27. Preobrazhensky SN, Bahler DW. Optimization of flow cytometric measurement of ZAP-70 in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2008; 74: 118–127.
28. Smolej L, Saudková L, Špaček M, Kozák T. ZAP-70 u chronické B-lymfocytární leukemie: klinický význam a metody detekce. Vnitř Lék 2006; 52: 1194–1199.
29. Poulain S, Benard C, Daudignon A, Le Baron F, Morel P, Duthilleul P. Is ZAP-70 expression stable over time in B chronic lymphocytic leukaemia? Leuk Lymphoma 2007; 48: 1219–1221.
30. Smolej L, Vroblova V, Novosad J. Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease. Int J Lab Hematol 2008; 30: 259–260.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 2
Most read in this issue
- Microchimerism – on the edge of incipient AML relapse?
- Clonal evolution in chronic lymphocytic leukemia
- Interfant 99 – treatment reflecting unique biology of the infant acute lymphoblastic leukemia. The results in the Czech Republic
- Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome